KTTA: Amendment: SEC Form SCHEDULE 13G/A filed by Pasithea Therapeutics Corp.
Stocks in this Quantisnow insightHealth Care
Historical context for KTTA
Across the 11 sessions after earlier KTTA headlines, the stock closed higher 6 times and lower 5 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | KTTA | SPY |
|---|---|---|---|
| May 4, 2026 | Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer | +0.7% | -0.4% |
| Apr 20, 2026 | Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) | -3.4% | -0.2% |
| Apr 1, 2026 | Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity | +0.3% | +0.8% |
| Feb 17, 2026 | Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference | -2.5% | +0.2% |
| Jan 13, 2026 | Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | -3.3% | -0.2% |
| Dec 2, 2025 | Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock | +2.6% | +0.2% |
Quantisnow market dataNASDAQ
KTTA
Pasithea Therapeutics Corp.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for KTTA
Full KTTA profile on Quantisnow Follow KTTA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time